v3.25.2

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 32,301	$ 27,260
Marketable securities	176,658	190,062
Prepaid expenses and other assets	10,363	12,303
Total current assets:	219,322	229,625
Property and equipment, net	549	614
Operating lease right-of-use assets	9,151	9,669
Marketable securities		35,621
Restricted cash	975	975
Other long-term assets	12	59
Total assets	230,009	276,563
Current liabilities:
Accounts payable	913	3,130
Accrued expenses	9,418	8,594
Current portion of operating lease liabilities	1,138	1,052
Total current liabilities	11,469	12,776
Operating lease liabilities, net of current portion	9,157	9,742
Total liabilities	20,626	22,518
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at June 30, 2025 and December 31, 2024; 71,234,510 and 71,130,054 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	7	7
Additional paid-in capital	817,864	808,190
Accumulated other comprehensive income	248	157
Accumulated deficit	(608,736)	(554,309)
Total stockholders' equity	209,383	254,045
Total liabilities and stockholders' equity	230,009	276,563
Series A Non-Voting Convertible Preferred Stock
Stockholders' equity:
Series A non-voting convertible preferred stock, $0.0001 par value; 100,000,000 shares authorized at June 30, 2025 and December 31, 2024; 70,601 shares issued and outstanding at June 30, 2025 and December 31, 2024	$ 0	$ 0

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Ventyx Biosciences, Inc. 10-Q